1017results about "Tetracycline active ingredients" patented technology

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Antibiotic for use in a method comprising systemically administering a photosensitive antibiotic to a subject having a microbial infection in a target tissue to provide a blood plasma concentration of the antibiotic in the subject; allowing the plasma or tissue concentration of the antibiotic increase to a predetermined level; and subjecting the target tissue to photodynamic therapy in order to increase the antimicrobial action of the antibiotic in the target tissue. With light activation the efficacy of the photosensitizer antibiotic can be enhanced, the spectrum of the microbial effect broadened and even an antiviral effect can be obtained. Generally, the present invention can be exploited when there is a need for enhancement of the local antimicrobial effect of antibiotics.

The present invention relates to tetracycline derivatives and their use as medicaments, in particular in the treatment or prevention of diseases selected from the group comprising or consisting of amyloidosis, pain, neurodegenerative diseases and neuroinflammatory diseases.

Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and / or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.

The invention relates to a preparation method of an efficient antibacterial material based on bionic design. The method comprises the following steps: step A, synthesizing a piezoelectric antibacterial material; and step B, combining the piezoelectric antibacterial material and a targeting material through a liposome carrier to prepare a bionic bacteriophage. According to the scheme, an innovative bionic bacteriophage concept is provided, a simple and intelligent antibacterial system is developed, reactive oxygen species (ROS) in a bacterial microenvironment is stimulated to be improved through energy conversion, bacterial cell membranes, protein and DNA are destroyed, and therefore antibacterial treatment is carried out.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

The invention discloses a preparation method of omasycine tosylate for injection, and belongs to the technical field of pharmaceutical preparations. The preparation method of the olmacycline tosylate for injection comprises the following steps: filtering a mixture solution containing the olmacycline tosylate, the cane sugar, the pH regulator and the water for injection, filling and sealing, and freeze-drying to obtain the olmacycline tosylate for injection. According to the preparation method, the problem that in the prior art, intermediate product liquid medicine is not completely dissolved is solved, the prepared freeze-dried product is free of the problems of atrophy, collapse, bottom sticking, layering and the like, the preparation method is simple, easy to operate and reliable, the obtained freeze-dried product is low in moisture content and impurity content, the stability is improved, and the product quality is guaranteed.

The invention relates to a nano preparation for delivering antibiotics based on plant extracts and application of the nano preparation, and belongs to the technical field of nano preparations. In order to solve the problems of low bioavailability and low action efficiency of oral administration or intravenous injection of antibiotics in the lung disease treatment process, the invention provides a nano preparation for delivering antibiotics based on plant extracts. The mass volume ratio of the antibiotics to the plant extract in the nano preparation is (1-10) mg: (20-100) mu L. The nano preparation disclosed by the invention can obviously inhibit the migration of fibroblasts, has an obvious bacteriostatic effect and can reduce the density of microorganisms in lungs; positive charges carried by the material are combined with negative charges on the surface of a bacterial cell membrane, transmembrane substance transfer on the bacterial cell membrane is affected, bacterial metabolism and reproduction are affected, adjustment of pulmonary symbiotic bacteria is better achieved, and the pulmonary fibrosis progress can be relieved. The nano preparation has the advantages of small toxic and side effects, good patient compliance, high encapsulation efficiency and the like.

Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.

Provided herein are pharmaceutical formulations and pharmaceutical compound salts which utilize complexing agents as counterions. Such formulations and salts are useful for treating a variety of disease and disorders. Provided herein are also treatment methods using the pharmaceutical compounds, pharmaceutical compositions, and pharmaceutically acceptable salts of the present disclosure.

The present invention discloses a drug conjugate based on ε-poly-L-lysine, its intermediate and its use. The present invention provides an ε-poly-L-lysine derivative-drug conjugate compound having a controllable number of group bonds and a controllable number of group bond sites as shown in formula (I). The drug conjugate of the present invention has one or more advantages of low renal clearance, low hepatic clearance and low splenic clearance, long plasma half-life, rapid accumulation of effective drug concentration in the lesion, and better therapeutic effect. [Case 1] TIFF2024542139000558.tif28169

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

Improved systems, compositions, and methods of treating infections with antimicrobials are provided, having reduced risk of creating or promoting drug- resistant microbes or superinfections, where one or more antimicrobials susceptible to drug-resistant organisms are applied via an aerosol delivery device in combination with an EDTA solution at elevated pH.

A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

The invention discloses an oxytetracycline injection and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the oxytetracycline is firstly micronized, then sprayed with water, frozen, heated and dried, soaked in a solution containing a surfactant, taken out and dried, and pretreated oxytetracycline is obtained; s2, water for injection is taken and heated, an antioxidant is added for dissolution, then a complexing agent is added, stirring is performed for dissolution, and a first solution is obtained; adding an organic solvent into the first solution, heating, adding the pretreated oxytetracycline, stirring and dissolving to obtain a second solution; adding a stabilizer into the second solution, and adjusting the pH value; and then supplementing the water for injection to obtain the injection. The oxytetracycline raw medicine powder is micronized to a specific particle size range, then freeze drying is performed to make the oxytetracycline raw medicine powder loose and porous, and compatibilization of the surfactant is further combined, so that the solubility and the stability of the oxytetracycline raw medicine powder are greatly improved in the subsequent injection preparation process.

The invention discloses a degradable nanocellulose sustained-release drug-loaded film and a preparation method thereof, and belongs to the technical field of drug functional materials. The preparation method comprises the following steps: mixing and stirring microcrystalline cellulose and 64wt% sulfuric acid solution, centrifuging, dialyzing to be neutral, and freeze-drying to obtain CNCs; cNCs, NaIO4 and water are mixed and then subjected to a light-shielding reaction, ethanol precipitation is added, dialysis purification is conducted, freeze drying is conducted, and formylation modified CNCs are obtained; mixing and stirring the aldehyde modified CNCs, sericin, polyvinyl alcohol, water and a target drug to obtain a core layer solution; dissolving a polylactic acid-glycolic acid copolymer into a mixed solution of chloroform and DMF (Dimethyl Formamide) to obtain a shell solution; the core layer solution and the shell layer solution are subjected to coaxial electrostatic spinning forming to obtain the drug-loaded fiber, then the drug-loaded fiber is subjected to biomimetic mineralization surface modification to obtain the degradable nanocellulose sustained-release drug-loaded film, the drug loading rate is increased, the mechanical property of the drug-loaded film is improved, and the sustained-release and release-controllable effects are achieved.

Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and / or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.

Improved systems, compositions, and methods of treating infections with antimicrobials are provided, having reduced risk of creating or promoting drug-resistant microbes or superinfections, where one or more antimicrobials susceptible to drug-resistant organisms are applied via an aerosol delivery device in combination with an EDTA solution at elevated pH.

The invention relates to a silicon-based nano material for targeted therapy of brucellosis as well as a preparation method and application of the silicon-based nano material. The invention relates to a preparation method of a silicon-based nano material for targeted therapy of brucellosis. The preparation method comprises the following steps: (1) preparing magnetic mesoporous silica; (2) aminating the magnetic mesoporous silica, and modifying the magnetic mesoporous silica with a responsive material and yeast beta-glucan to obtain modified magnetic mesoporous silica; and (3) carrying out antibiotic loading on the modified magnetic mesoporous silica. According to the silicon-based nano material for targeted therapy of brucellosis as well as the preparation method and the application of the silicon-based nano material, the surface of magnetic macroporous mesoporous silica is modified with yeast beta-glucan capable of targeting M cells and glutathione responsive molecules, and a drug delivery system sensitive to a brucellosis environment is synthesized; the nano-carrier has targeted targeting selectivity for delivering and releasing drugs, the activity, slow release and target cell uptake efficiency of antibiotics are ensured, and the brucellosis treatment is more accurate and efficient.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention belongs to the technical field of medical materials, and particularly relates to high-strength dual-network self-healing hydrogel as well as a composition, a preparation method and application thereof. The composition for preparing the high-strength dual-network self-healing hydrogel comprises a composition A for constructing a first network system of the hydrogel and a composition B for constructing a second network system of the hydrogel, wherein the composition A comprises modified chitosan and modified hyaluronic acid, and the composition B comprises polyvinyl alcohol and sodium tetraborate; the volume ratio of the polyvinyl alcohol to the modified chitosan to the modified hyaluronic acid is (5-7): (5-7): 1; the concentration of the modified chitosan is 2-4 wt%, the concentration of the modified hyaluronic acid is 8-12 wt%, and the concentration of the polyvinyl alcohol is 18-22 wt%. The high-strength dual-network self-healing hydrogel prepared on the basis of the composition has relatively high mechanical performance and excellent self-healing performance, and also has excellent resilience performance, swelling performance, shape memory and ionic conduction behavior.

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

The present invention relates to methods and compositions for the prevention and / or treatment of pyelonephritis and / or urinary sepsis.